NCT05524493 High-field MR Imaging in Migraine, Visual Snow and Epilepsy
| NCT ID | NCT05524493 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Migraine |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-03-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this project, the aim is to recruit patients with drug resistant epilepsy and those suffering from migraine. Interestingly, patients suffering from epilepsy are also more often reporting to suffer from migraine. The pathobiology is understudied, but it is believed that both etiologies results from brain networks changes. A clinical certified 7T Terra Siemens scanner will be employed to assess in all participants (including healthy controls) how the microstructure differs in disease specific areas. Patients will further be clinically assessed as well as undergo questionnaires. Migraine is also a common comorbidity to visual snow syndrom and has been shown to impact similar brain regions. However, the pathophysiology is still understudied and a better understanding of the two diseases is needed.
Eligibility Criteria
Inclusion Criteria: Patients: * Patient must be able to read and sign the informed consent form * Stable prophylactic medication for 2 months prior to MRI * At leat one of the two criteria applies: * Patients diagnosed with migraine (with or without aura, episodic or chronic). Diagnosis is ensured by clinical interview (at least 8 weeks prior to MRI). Also, patients complete a migraine questionnaire (HARDSHIP) (at least 8 weeks before MRI). Migraine frequency ≥ 2 migraine attacks/month. * Patients with drug resistent epilepsy accroding to ILAE crtieria * Patients with diagnoses of Visual snow syndrome Healthy participants; * No migraine (validated by questionnaire) or epilepsy * Participants must be able to read and sign the informed consent form Exclusion Criteria: * Treatment of migraine disease with Botox within \< 4 months before baseline and during the study period * Pregnant or breastfeeding women * Intention during the course of the trial to become pregnant * Women with bilateral ovariectomy, with or without hysterectomy, and postmenopausal women (\>2 years of age) are not considered childbearing. * Other clinically significant comorbidities (e.g., renal insufficiency, hepatic dysfunction, cardiovascular disease, etc.), * Known or suspected noncompliance with the protocol, drug or alcohol abuse, * Patient's inability to follow trial procedures, e.g., due to language problems, mental illness, dementia, etc., * Prior participation in the clinical trial * Enrolment of the investigator, his/ her family members, employees and other dependent persons of the test personnel * Metallic objects in the body (e.g., splinters, MR incompatible implants). * Pacemaker * Claustrophobia * Obesity (body mass index \> 35 kg/m2)
Contact & Investigator
Patrick Freund, Prof. Dr. med. Dr. rer. nat.
PRINCIPAL INVESTIGATOR
University of Zurich
Frequently Asked Questions
Who can join the NCT05524493 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05524493 currently recruiting?
Yes, NCT05524493 is actively recruiting participants. Contact the research team at lynn.farner@balgrist.ch for enrollment information.
Where is the NCT05524493 trial being conducted?
This trial is being conducted at Zurich, Switzerland, Zurich, Switzerland.
Who is sponsoring the NCT05524493 clinical trial?
NCT05524493 is sponsored by University of Zurich. The principal investigator is Patrick Freund, Prof. Dr. med. Dr. rer. nat. at University of Zurich. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.